Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapy

Exp Dermatol. 2023 May;32(5):707-709. doi: 10.1111/exd.14717. Epub 2022 Dec 1.

Authors

Julia Elisabeth Fromme^{1

2}, Reinhard Dummer³, Cornelia Mauch¹, Paola Zigrino¹

Affiliations

¹ Department of Dermatology and Venereology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Germany.
³ Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

PMID: 36437681
DOI: 10.1111/exd.14717

No abstract available

Keywords: extracellular matrix; melanoma; targeted therapy; tenascin C.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Extracellular Matrix
Humans
Melanoma* / drug therapy
Mitogen-Activated Protein Kinases / antagonists & inhibitors
Protein Kinase Inhibitors / therapeutic use
Tenascin*

Substances

Tenascin
Mitogen-Activated Protein Kinases
Protein Kinase Inhibitors